Tamoxifen eliminates estrogen’s neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system
- 62 Downloads
The capacity for 17-a and 17-B estradiol to modulate MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system and potential antagonism of this modulation by the anti-estrogen, tamoxifen, were evaluated. Treatment of retired breeder ovariect-omized C57/BI mice with17-B estradiol diminished the amount of striatal dopamine reduction resulting from MPTP treatment with striatal dopamine concentrations of these17-B estradiol treated mice failing to differ significantly from vehicle treated controls. A combined administration of17-B estradiol with tamoxifen abolished this neuroprotective effect of estrogen as striatal dopamine concentrations of this group were significantly lower than vehicle treated controls. Results to17-a estradiol were less effective since striatal dopamine concentrations of these mice following MPTP treatment were significantly decreased as compared with vehicle controls. In contrast to the nigrostriatal dopaminergic system, no statistically significant effects of these treatments were observed upon olfactory bulb dopamine concentrations. Taken together, these results show that17-B, but not an equivalent concentration of17-a, estradiol was effective in decreasing striatal dopamine neurotoxicity to MPTP. This effect of 17-Bestradiol was abolished by tamoxifen. These data have important implications regarding the mechanisms of estrogen-tamoxifen interactions within the nigrostriatal dopaminergic system as well as for clinical applications of tamoxifen within pre-menopausal women.
KeywordsDopamine Striatum Olfactory Bulb Estradiol Parkinson’s Disease Neurodegeneration Cancer
Unable to display preview. Download preview PDF.
- Ali, S. F. and Freyaldenhoven, T.E. (1999) MPTP — A model of Parkinson’s disease. In Bondy, S. C. (Ed): Chemicals and Neurodegenerative Disease (Scottsdale, AZ; Prominent Press), pp. 162–188.Google Scholar
- Behl, C, Skutella, T., Lezoualc’h, F., Post, A., Widmann, M., Newton, C. J. and Holsboer, F. (1997) Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Molec. Pharmacol.51, 535–541.Google Scholar
- Brooks, W. J., Jarvis, M. F. and Wagner, G. C. (1998) Influence of sex, age and strain of MPTF-induced neurotoxicity. Res. Comm. Subst. Abuse10, 181–184.Google Scholar
- Dluzen, D. E., Disshon, K. A. and McDermott, J. L. (1998) Estrogen as a modulator of striatal dopaminergic neurotoxicity. In Marwah, J. and Teitelbaum, H. (Eds) Recent Advances in Neurodegenerative Disorders (Scottsdale, AZ; Prominent Press), pp. 149–192.Google Scholar
- Dluzen, D. E. and McDermott, J. L. (2000a) Gender differences in the neurotoxicity of the nigrostriatal dopaminergic system: Implications for parkinson’s disease. J. Gender-Specific Med.3, 36–42.Google Scholar
- Dluzen, D. E., McDermott, J. L. and Liu, B. (1996a) Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal concentrations and release. J. Neuro-chem.66, 658–666.Google Scholar
- Gao, X. and Dluzen, D. E. (2000) Tamoxifen abolishes estrogen’s neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience — submitted.Google Scholar
- Grandbois, M., Tanguay, B. and Di Paolo, T. (1999) Estradiol and dehydroepiandrosterone but not dihydrotestoster-one protect against MPTP-induced dopamine depletion in mice. Soc. Neurosci.25, 1595 (Abstract).Google Scholar
- Green, P. S., Bishop, J. and Simpkins, J. W. (1997) 17-estra-diol exerts neuroprotective effects on SK-N-SH cells. J. Neurosci.15, 511–515.Google Scholar
- Miller, D. B. (1998) Endocrine disruption: estrogen androgen and the nervous system. In Tilson, H. A. and Harry, G. J. (Eds.) Neurotoxicology (Taylor & Francis), pp. 201-217.Google Scholar